Literature DB >> 14592913

Standards of measurements in myasthenia gravis.

P Gajdos1, T Sharshar, S Chevret.   

Abstract

Valid and reliable measurements of muscle impairment are needed to assess therapeutic efficacy in patients with generalized myasthenia gravis. Several muscle scoring systems have been proposed for assessing muscle strength in such patients. The aim of the present study is to assess the validity and interobserver agreement of these muscle scores.

Entities:  

Mesh：

Year:  2003        PMID： 14592913     DOI： 10.1196/annals.1254.058

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  5 in total

1.  Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors:  Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal:  JCI Insight       Date:  2017-04-06

2.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

3.  A conceptual framework for evaluating impairments in myasthenia gravis.

Authors:  Carolina Barnett; Vera Bril; Moira Kapral; Abhaya Kulkarni; Aileen M Davis
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

Review 4.  Plasma exchange for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2002

5.  The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial.

Authors:  Simone Birnbaum; Jean-Yves Hogrel; Raphael Porcher; Pierre Portero; Bernard Clair; Bruno Eymard; Sophie Demeret; Guillaume Bassez; Marcela Gargiulo; Estelle Louët; Sonia Berrih-Aknin; Asmaa Jobic; Philippe Aegerter; Philippe Thoumie; Tarek Sharshar
Journal:  Trials       Date:  2018-01-18       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.